Is Day One Biopharmaceuticals, Inc. (DAWN) a good stock to buy?

Olyth's institutional analysis of DAWN reveals an Altman Z-Score of 18.73 and a Piotroski F-Score of 3/9. These metrics, combined with its 5-year revenue trend ($0.16B most recent), help investors decide if DAWN fits their risk profile.

What is the current P/E ratio for DAWN?

As of the latest trading session, Day One Biopharmaceuticals, Inc. (DAWN) has a trailing P/E ratio of -20.65.

Who is the CEO of Day One Biopharmaceuticals, Inc.?

The current Chief Executive Officer of Day One Biopharmaceuticals, Inc. is Jeremy Bender.

What was DAWN's revenue for the last 5 years?

According to its latest income statements, Day One Biopharmaceuticals, Inc. reported annual revenues of $0.16B (2025), $0.13B (2024), $0.00B (2023), $0.00B (2022), $0.00B (2021) respectively.

Does DAWN pay a dividend?

Day One Biopharmaceuticals, Inc. does not currently pay a dividend to its shareholders.

How much debt and cash flow does DAWN have?

In its latest reporting period, Day One Biopharmaceuticals, Inc. generated $-0.10B in Free Cash Flow against a total debt load of $0.00B.

What is the Price-to-Book (P/B) ratio of Day One Biopharmaceuticals, Inc.?

The Price-to-Book (P/B) ratio for Day One Biopharmaceuticals, Inc. (DAWN) is currently 5.02.

What is the Price-to-Sales (P/S) ratio of DAWN?

Based on trailing twelve-month data, Day One Biopharmaceuticals, Inc. (DAWN) trades at a Price-to-Sales (P/S) ratio of 14.00.

What is Day One Biopharmaceuticals, Inc.'s Return on Equity (ROE)?

Day One Biopharmaceuticals, Inc. (DAWN) has a Return on Equity (ROE) of -23.43%, representing its profitability relative to shareholder equity.

DAWN

Day One Biopharmaceuticals, Inc. · Healthcare

21.44

0.09%(-0.02)

Market Open

Last Updated: — ET

52W L: $5.6352W H: $21.47

$21.44

CHG+0.30 (+1.42%)

H$21.78

L$21.04

VOL68M

DAWN (1h)

Company Profile

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

Sector

Healthcare

Industry

Biotechnology

Employees

181

IPO Date

2021-05-27

Beta

-1.75

Websitedayonebio.com↗

DAWN

Day One Biopharmaceuticals (NASDAQ:DAWN) Sets New 1-Year High – What’s Next?

Day One Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Day One Biopharmaceuticals, Inc. - DAWN

Here Are Wednesday’s Top Wall Street Analyst Research Calls: CrowdStrike, Harley-Davidson, Intuitive Surgical, Medline, Nike, Oracle, Planet Fitness, Vici Properties, and More

Day One Biopharmaceuticals Touts OJEMDA Sales Surge, Sets $225M-$250M 2026 Outlook at TD Cowen

Here Are Tuesday’s Top Wall Street Analyst Research Calls: AT&T, Amgen, CrowdStrike, Gilead, Hims & Hers, Intuit, Lowe’s, Qualcomm, Rivian, Strategy and More

Are DAWN and TALK Obtaining Fair Deals for their Shareholders?